155 related articles for article (PubMed ID: 37424900)
1. Fibroblast growth factor 21 resistance is associated with body shape in patients with type 2 diabetes complicating hypertension.
Gan J; Duan Z; Tang L; Liu Z; Tian H; Wu M; Bi Y; Pan X; Wang W; Gao X; Wang N; Lin Z; Yang H
Front Cardiovasc Med; 2023; 10():1168047. PubMed ID: 37424900
[TBL] [Abstract][Full Text] [Related]
2. Increased circulating FGF21 level predicts the burden of metabolic demands and risk of vascular diseases in adults with type 2 diabetes.
Liu Z; Peng Y; Li S; Lin Y; Huang Y; Chen W; Bao C; Zhou Z; Lin Z; Chen L
BMC Endocr Disord; 2023 Dec; 23(1):272. PubMed ID: 38057786
[TBL] [Abstract][Full Text] [Related]
3. Serum Fibroblast Growth Factor 21 Levels Are Positively Associated with Metabolic Syndrome in Patients with Type 2 Diabetes.
Gao RY; Hsu BG; Wu DA; Hou JS; Chen MC
Int J Endocrinol; 2019; 2019():5163245. PubMed ID: 31582974
[TBL] [Abstract][Full Text] [Related]
4. Fibroblast Growth Factor 21 and Fetuin-A in Obese Adolescents With and Without Type 2 Diabetes.
Reinehr T; Karges B; Meissner T; Wiegand S; Fritsch M; Holl RW; Woelfle J
J Clin Endocrinol Metab; 2015 Aug; 100(8):3004-10. PubMed ID: 26052728
[TBL] [Abstract][Full Text] [Related]
5. Plasma fibroblast growth factor 21 levels increase with ectopic fat accumulation and its receptor levels are decreased in the visceral fat of patients with type 2 diabetes.
Hong ES; Lim C; Choi HY; Lee YK; Ku EJ; Moon JH; Park KS; Jang HC; Choi SH
BMJ Open Diabetes Res Care; 2019; 7(1):e000776. PubMed ID: 31798902
[TBL] [Abstract][Full Text] [Related]
6. Association of plasminogen activator inhibitor-1 and fibroblastic growth factor 21 in 3 groups of type 2 diabetes: Without overweight/obesity, free of insulin resistance, and without hepatosteatosis.
Takebe N; Hasegawa Y; Matsushita Y; Chiba H; Onodera K; Kinno H; Oda T; Nagasawa K; Segawa T; Takahashi Y; Okada K; Ishigaki Y
Medicine (Baltimore); 2023 Sep; 102(35):e34797. PubMed ID: 37657012
[TBL] [Abstract][Full Text] [Related]
7. Serum fibroblast growth factor 21 concentrations in type 2 diabetic retinopathy patients.
Esteghamati A; Momeni A; Abdollahi A; Khandan A; Afarideh M; Noshad S; Nakhjavani M
Ann Endocrinol (Paris); 2016 Oct; 77(5):586-592. PubMed ID: 27106505
[TBL] [Abstract][Full Text] [Related]
8. Circulating Fibroblast Growth Factor 21 and Total Testosterone in Type 2 Diabetes Mellitus Men With Coronary Heart Disease.
Mei Y; Lyu Y; Zhao Z; Li Y
Front Endocrinol (Lausanne); 2022; 13():912243. PubMed ID: 35909513
[TBL] [Abstract][Full Text] [Related]
9. Serum fibroblast growth factor 21 was elevated in subjects with type 2 diabetes mellitus and was associated with the presence of carotid artery plaques.
An SY; Lee MS; Yi SA; Ha ES; Han SJ; Kim HJ; Kim DJ; Lee KW
Diabetes Res Clin Pract; 2012 May; 96(2):196-203. PubMed ID: 22293928
[TBL] [Abstract][Full Text] [Related]
10. Klotho and fibroblast growth factors 19 and 21 serum concentrations in children and adolescents with normal body weight and obesity and their associations with metabolic parameters.
Socha-Banasiak A; Michalak A; Pacześ K; Gaj Z; Fendler W; Socha A; Głowacka E; Kapka K; Gołąbek V; Czkwianianc E
BMC Pediatr; 2020 Jun; 20(1):294. PubMed ID: 32546231
[TBL] [Abstract][Full Text] [Related]
11. Exenatide treatment decreases fasting fibroblast growth factor 21 levels in patients with newly diagnosed type 2 diabetes mellitus.
Hu Y; Liu J; Zhang H; Xu Y; Hong T; Wang G
Diabetes Metab; 2016 Nov; 42(5):358-363. PubMed ID: 27178737
[TBL] [Abstract][Full Text] [Related]
12. Liraglutide Decreases Liver Fat Content and Serum Fibroblast Growth Factor 21 Levels in Newly Diagnosed Overweight Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease.
Li X; Wu X; Jia Y; Fu J; Zhang L; Jiang T; Liu J; Wang G
J Diabetes Res; 2021; 2021():3715026. PubMed ID: 34660809
[TBL] [Abstract][Full Text] [Related]
13. Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity.
Mraz M; Bartlova M; Lacinova Z; Michalsky D; Kasalicky M; Haluzikova D; Matoulek M; Dostalova I; Humenanska V; Haluzik M
Clin Endocrinol (Oxf); 2009 Sep; 71(3):369-75. PubMed ID: 19702724
[TBL] [Abstract][Full Text] [Related]
14. Serum fibroblast growth factor 21 levels is associated with lower extremity atherosclerotic disease in Chinese female diabetic patients.
Zhang X; Hu Y; Zeng H; Li L; Zhao J; Zhao J; Liu F; Bao Y; Jia W
Cardiovasc Diabetol; 2015 Mar; 14():32. PubMed ID: 25850006
[TBL] [Abstract][Full Text] [Related]
15. Patterns of Circulating Fibroblast Growth Factor 21 in Subjects with and without Type 2 Diabetes.
Lu J; Yu H; Mo Y; Ma X; Hao Y; Lu W; Li H; Bao Y; Zhou J; Jia W
PLoS One; 2015; 10(11):e0142207. PubMed ID: 26540514
[TBL] [Abstract][Full Text] [Related]
16. The serum fibroblast growth factor 21 is correlated with retinopathy in patients with type 2 diabetes mellitus.
Heidari Z; Hasanpour M
Diabetes Metab Syndr; 2021; 15(6):102296. PubMed ID: 34592531
[TBL] [Abstract][Full Text] [Related]
17. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans.
Zhang X; Yeung DC; Karpisek M; Stejskal D; Zhou ZG; Liu F; Wong RL; Chow WS; Tso AW; Lam KS; Xu A
Diabetes; 2008 May; 57(5):1246-53. PubMed ID: 18252893
[TBL] [Abstract][Full Text] [Related]
18. The relationship between serum levels of fibroblast growth factor 21 and diabetic retinopathy.
Mousavi Z; Bonakdaran S; Sahebkar A; Yaghoubi G; Yaghoubi MA; Davoudian N; Mohebbi M
EXCLI J; 2017; 16():1249-1256. PubMed ID: 29285020
[TBL] [Abstract][Full Text] [Related]
19. Prediction of a new body shape index and body adiposity estimator for development of type 2 diabetes mellitus: The Rural Chinese Cohort Study.
Han C; Liu Y; Sun X; Luo X; Zhang L; Wang B; Ren Y; Zhou J; Zhao Y; Zhang D; Liu X; Zhang M; Hu D
Br J Nutr; 2017 Nov; 118(10):771-776. PubMed ID: 29143718
[TBL] [Abstract][Full Text] [Related]
20. Opposite alterations in FGF21 and FGF19 levels and disturbed expression of the receptor machinery for endocrine FGFs in obese patients.
Gallego-Escuredo JM; Gómez-Ambrosi J; Catalan V; Domingo P; Giralt M; Frühbeck G; Villarroya F
Int J Obes (Lond); 2015 Jan; 39(1):121-9. PubMed ID: 24813368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
